Studentship
AZ funded Non-clinical PhD Studentship (Fixed Term) in selective nanoparticle targeting of senescent alveolar epithelium using an alveolar organoid model
University of Cambridge
- PhD
- United Kingdom
- Apply to an advertised position
About
Develop nanoparticle delivery of senescence-modulating therapies to lung epithelial cells in a Cambridge–AstraZeneca doctoral project. Research uses human alveolar organoids, engineered carriers and automated screening to evaluate drug selection, delivery and functional responses relevant to pulmonary fibrosis. The four-year studentship begins in October 2027.
Topics
- nanoparticle delivery, broader topic: delivery
- senescence-modulating therapies, search World Wide
- lung epithelial cells, broader topic: cells
- human alveolar organoids, broader topic: organoids
- engineered carriers, search World Wide
- automated screening, search World Wide
- drug selection, search World Wide
- pulmonary fibrosis, search World Wide
- functional responses
- Cambridge–AstraZeneca
Eligibility
Covers: Four years of funding from 1 October 2027, including a maintenance allowance of £21,500 per year and the University Composition Fee subject to the stated fee-eligibility conditions.
Research is hosted at the University of Cambridge, United Kingdom. Home-fee or additional-scholarship conditions apply to overseas applicants.
Applicants need or should expect a first or upper-second-class degree, or overseas equivalent, in a subject that prepares them for cell-biology research. UK citizens and overseas applicants meeting Home-fee requirements may apply; other overseas applicants need additional scholarship funding for the fee difference. Self-funding the difference is not allowed.
Source: cam.ac.uk